Overview
Cardiogen is a synthetic cardiovascular bioregulator tetrapeptide (AEDR: Ala-Glu-Asp-Arg) researched for cellular repair and cardioprotective properties. Preclinical studies suggest it enters cells and modulates survival pathways, supporting cytoskeletal integrity and reducing apoptosis in stressed cardiac tissue while encouraging apoptosis in abnormal cells.
What It Is
A four-amino-acid peptide designed to function as a gene expression bioregulator operating at the cellular and nuclear level. Research demonstrates it upregulates structural proteins including actin, tubulin, vimentin, and nuclear lamins, thereby supporting cytoskeletal integrity.
Reconstitution Instructions
Standard Approach (3 mL dilution):
– Add 3.0 mL bacteriostatic water to the 20 mg vial
– Final concentration: ~6.67 mg/mL
– Inject slowly down vial wall; avoid foaming
– Gently swirl/roll until dissolved (do not shake)
– Label and refrigerate at 2–8 °C, protected from light
Measurement convenience:
At 6.67 mg/mL, 1 unit on a U-100 insulin syringe = 0.01 mL ≈ 66.7 mcg
Dosage Protocol
Gradual Titration Schedule
| Week | Daily Dose | Units (U-100 syringe) | mL |
|---|---|---|---|
| 1–2 | 200 mcg | 3 units | 0.03 mL |
| 3–4 | 300 mcg | 4.5 units | 0.045 mL |
| 5 | 400 mcg | 6 units | 0.06 mL |
| 6–12 | 500 mcg | 7.5 units | 0.075 mL |
Frequency: Once daily via subcutaneous injection
Cycle Length: 8–12 weeks; optional extension to 16 weeks
Timing: Any consistent time; rotate injection sites daily
How It Works
The peptide promotes cell repair and reduces programmed cell death in stressed or damaged tissue. It appears to suppress overactive p53-mediated apoptosis signals under stress conditions, allowing healthy cells to survive injury while paradoxically encouraging apoptosis in abnormal or cancerous cells. In rodent cardiac studies, daily administration reduced post-myocardial infarction mortality approximately threefold, preserved cardiac tissue architecture, and maintained higher glycogen reserves in heart muscle cells.
Potential Benefits
– Demonstrated cardioprotective effects in rodent myocardial infarction models, reducing mortality and necrotic tissue formation
– Stimulates cardiomyocyte and fibroblast proliferation while decreasing pro-apoptotic factors
– Shows selective dual action: protects healthy cells while promoting apoptosis in tumor cells
– Preserves metabolic function in cardiac tissue, maintaining glycogen stores and mitochondrial integrity during stress
– Enhances metabolic resilience by improving mitochondrial integrity
Side Effects & Warnings
– No human clinical data available; all evidence derives from laboratory and animal research
– Generally well tolerated in preclinical models
– Occasional mild injection-site reactions possible with subcutaneous administration
– This content is for research purposes only and does not constitute medical advice
Storage Instructions
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2–4 weeks with bacteriostatic water
Critical: Avoid freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation uptake
Supplies Needed (8–16 week protocol)
– Peptide Vials: 2–3 vials (depending on cycle length)
– U-100 Insulin Syringes: 56–112 syringes (7 per week)
– Bacteriostatic Water: 1 × 10 mL bottle per 2 vials
– Alcohol Swabs: 2–3 × 100-count boxes (14 per week)
Injection Technique
– Clean vial stopper and skin with alcohol; allow complete drying
– Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
– Do not aspirate for subcutaneous injections
– Inject slowly and steadily
– Rotate sites systematically: abdomen (2+ inches from navel), outer thighs, upper arms
– Apply gentle pressure post-injection with clean gauze; do not rub
– Dispose of syringes immediately in a sharps container
Important Notes
– Use new sterile insulin syringes for each injection
– Document daily dose and site rotation for consistency
– Consider 30- or 50-unit insulin syringes for improved precision with small volumes
– Maintain consistent timing to establish stable plasma levels
– Document any observable effects systematically throughout the research period
Disclaimer
This protocol is intended for research and educational purposes only. Cardiogen is sold for research use only. No human clinical trials have been published; all dosing information is extrapolated from preclinical studies. Consult qualified professionals before implementing any research protocol. This information does not constitute medical advice, diagnosis, or treatment.